Eldepryl

(Selegiline)

ApprovedSmall molecule

QQuagen

Eldepryl is one of 277 small molecule programs targeting Nicotine Dependence. It is currently in Approved.

Indications

Total Trials

Active Trials

276

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Nicotine DependenceActive, not recruiting

Prostate AdenocarcinomaActive, not recruiting

Erectile DysfunctionActive, not recruiting

Borderline Personality DisorderActive, not recruiting

Cocaine DependenceActive, not recruiting

Adverse EffectActive, not recruiting

SchizophreniaActive, not recruiting

Smoking CessationActive, not recruiting

Nicotine DependencePhase 2

Active, not recruiting

Prostate AdenocarcinomaPhase 2

Active, not recruiting

Erectile DysfunctionApproved

Active, not recruiting

Borderline Personality DisorderPhase 3

Active, not recruiting

Cocaine DependencePhase 2

Active, not recruiting

Adverse EffectApproved

Active, not recruiting

SchizophreniaPhase 1

Active, not recruiting

Smoking CessationPhase 2

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Eldepryl

QQuagen

Approved

1 2

Celexa

AbbVie

Preclinical

4 3

Inapsine

Alnylam Pharmaceuticals

Preclinical

1 4

Zocor

OOrganon and Co

Preclinical

6 5

Ibrance

Pfizer

Preclinical

—6

Luvox

SSolvay Pharmaceuticals

Preclinical

1 7

Persantine

Boehringer Ingelheim

Preclinical

1 8

Catapres

Boehringer Ingelheim

Preclinical

1 9

Vivarin

HHikma Pharmaceuticals LLC

Preclinical

1 10

Compazine

GGlaxo Dba Glaxosmithkline

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cocaine Dependence3 trials

Selegiline in Outpatient Treatment for Cocaine Dependence - 1

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 2·NCT00000336

Selegiline in Treatment of Cocaine Dependence - 2

Completed·UUniversity of Pennsylvania·Phase 2·NCT00000188·50 enrolled

Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 3·NCT00032929·269 enrolled

AIN2 trials

Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior

Completed·MMidwest Biomedical Research Foundation·Phase 2·NCT01495195·12 enrolled

Pharmacological Modulation of Cocaine Effects - 1

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 2·NCT00000201

Prostate Adenocarcinoma1 trial

Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma

Unknown status·LLászló Mangel·Phase 2·NCT04586543·110 enrolled

Nicotine Dependence1 trial

Selegiline Patch for Treatment of Nicotine Dependence

Completed·SStanford University·Phase 2·NCT01330030·243 enrolled

Excessive Daytime Sleepiness1 trial

Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease

Completed·SSecond Affiliated Hospital of Soochow University·Phase 4·NCT04870372·141 enrolled

8 more indications

Erectile Dysfunction1 trial

Sagene 2014 - Parkinson's Disease and Erectile Dysfunction

Unknown status·UUniversity of South Florida·Phase 4·NCT02225548·10 enrolled

Smoking1 trial

Usefulness of Selegiline as an Aid to Quit Smoking - 1

Completed·YYale University·Phase 2·NCT00129311·101 enrolled

Borderline personality disorder1 trial

Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder

Completed·MMood and Anxiety Research, Inc·Phase 3·NCT01912391·30 enrolled

Methamphetamine1 trial

Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1

Unknown status·NNational Institute on Drug Abuse (NIDA)·Phase 1·NCT00033072·16 enrolled

Infusion1 trial

Infusion Laboratory: Protocol 1 - Selegeline - 2

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 1·NCT00000337

Schizophrenia1 trial

Efficacy of Selegiline in Negative Symptoms of Schizophrenia

Completed·TTabriz University·Phase 1·NCT00456976·70 enrolled

Adverse Effect1 trial

Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists

Completed·PParkinson's Disease and Movement Disorder Center of Boca Raton·Phase 4·NCT00443872·77 enrolled

Smoking Cessation1 trial

Selegiline for Smoking Cessation - 1

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 2·NCT00439413·246 enrolled

Regulatory

FDA Approval Timeline[4]

Jun 5, 1989

SELEGILINE HYDROCHLORIDE

NDA NDA019334

May 15, 1996

ELDEPRYL

NDA NDA020647

Feb 27, 2006

EMSAM

NDA NDA021336

Jun 14, 2006

ZELAPAR

NDA NDA021479

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Selegiline. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Selegiline compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Selegiline. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021479). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Quagen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: QQuagen

Eldepryl

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cocaine Dependence3 trials

AIN2 trials

Prostate Adenocarcinoma1 trial

Nicotine Dependence1 trial

Excessive Daytime Sleepiness1 trial

Erectile Dysfunction1 trial

Smoking1 trial

Borderline personality disorder1 trial

Methamphetamine1 trial

Infusion1 trial

Schizophrenia1 trial

Adverse Effect1 trial

Smoking Cessation1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News